Skip to main content

Advertisement

Log in

The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

ABSTRACT

Background

Extensive clinical experience suggests that hyperthermic intraperitoneal chemotherapy (HIPEC) may play an important role in the management of colorectal cancer patients with peritoneal carcinomatosis (CRCPC). However, there remains no established nonsurgical process to rationally select patients for this management, either for inclusion/stratification in clinical trials or as a component of standard of care. The Peritoneal Surface Disease Severity Score (PSDSS) was introduced as a basis to improve patient selection.

Methods

The American Society of Peritoneal Surface Malignancies conducted a retrospective review of 1,013 CRCPC patients. The PSDSS was evaluated on 3 specific criteria obtained before surgery (symptoms, extent of peritoneal dissemination, and primary tumor histology). Overall survival was analyzed according to four tiers of disease severity, and a comparison was made between patients who underwent cytoreductive surgery + HIPEC and those who did not.

Results

The PSDSS was calculated on 884 patients (87 %). The median survival of 275 patients not undergoing CRS/HIPEC based on their PSDSS—I (n = 8), II (n = 80), III (n = 55), and IV (n = 132)—was 45, 19, 8, and 6 months, respectively. The median survival of 609 patients who underwent CRS/HIPEC based on their PSDSS—I (n = 75), II (n = 317), III (n = 82), and IV (n = 135)—was 86, 43, 29, and 28 months, respectively.

Conclusions

These data support that the PSDSS, undertaken before surgery, is capable of defining CRCPC populations who have a statistically defined high or considerably lower likelihood of long-term survival after CRS/HIPEC. The PSDSS can be quite useful in the decision to enter CRCPC patients into, and their stratification within, clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

FIG. 1
FIG. 2

Similar content being viewed by others

REFERENCES

  1. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecological malignancy: a prospective study of prognostic factors. Cancer. 1989;63:364–367.

    Article  CAS  PubMed  Google Scholar 

  2. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–1550.

    Article  CAS  PubMed  Google Scholar 

  3. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecological malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:58–63.

    Article  Google Scholar 

  4. Jacquet P, Vidal-Jove J, Zhu B, et al. Peritoneal carcinomatosis from gastrointestinal malignancy: natural history and new prospects for management. Acta Chir Belg. 1994;94:191–197.

    CAS  PubMed  Google Scholar 

  5. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institution study. J Clin Oncol. 2004;22:3284–3292.

    Article  CAS  PubMed  Google Scholar 

  6. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–685.

    Article  PubMed  Google Scholar 

  7. Chua TC, Esquivel J, Pelz JO, Morris DL. Summary of current therapeutic options for patients with peritoneal metastases from colorectal cancer. J Surg Oncol. 2013;107:566–573.

    Article  PubMed  Google Scholar 

  8. Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24:4011–4019.

    Article  PubMed  Google Scholar 

  9. Pelz O, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a Peritoneal Surface Disease Severity Score in patients with colon cancer and peritoneal dissemination. J Surg Oncol. 2009;99:9–15.

    Article  PubMed  Google Scholar 

  10. Chua TC, Morris DL, Esquivel J. Impact of the Peritoneal Surface Disease Severity Score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:1330–1336.

    Article  PubMed  Google Scholar 

  11. Esquivel J, Chua T, Stojadinovic A, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102:565–570.

    Article  CAS  PubMed  Google Scholar 

  12. Pelz JO, Chua TC, Esquivel J, et al. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer. 2010;10:689.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pool analysis of North Central Cancer Treatment Group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–267.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Klaver YLB, Simkens LHJ, Lemmens VEPP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617–623.

    Article  CAS  PubMed  Google Scholar 

  15. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomized control trial. Lancet. 2007;370:135–142 .

    Article  CAS  PubMed  Google Scholar 

  16. Tol J, Koopman M, Rodenburg CJ, et al. A randomized phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO 2 study of the Dutch Colorectal Cancer Group. An interim analysis of toxicity. Ann Oncol. 2008;19:734–738.

    Article  CAS  PubMed  Google Scholar 

  17. Comprehensive molecular characterization of human colon and rectal cancer. The Cancer Genome Atlas Network. Nature. 2012;487:330–337.

  18. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–3506.

    Article  PubMed  Google Scholar 

  19. Turaga K, Levine E, Barone R, et al. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the united states. Ann Surg Oncol. 2014;21:1501–1505.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jesus Esquivel MD.

Additional information

A video of the presentation of the data in this article at the 67th Annual Society of Surgical Oncology Cancer Symposium is available at http://www.surgonc.org/vm

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Esquivel, J., Lowy, A.M., Markman, M. et al. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Ann Surg Oncol 21, 4195–4201 (2014). https://doi.org/10.1245/s10434-014-3798-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-3798-z

Keywords

Navigation